Jump to content

Dax & Dow

Recommended Posts

Early check for support following a big run up into yesterday's close and continuing on upbeat trade war news overnight. The Dow ATH is the purple monthly chart resistance level just overhead so the bulls will be wary, they know next week's expected rate cut is fully priced but Powell is capable of wrong footing them yet again. I suspect if the ATH is broken it will be by drifting price action with one eye on retreat rather than a full rush dam burst.


Link to comment
4 minutes ago, dmedin said:

@Caseynotes You've done a good thing by reminding us to overlook the naysayers and look at the underlining up trend in the Wall Street index.  Thank you.

seen it before at every hint of a downturn and it drags the unwary down, I presume one day they will be right and you'll never hear the end of it but it's worth stepping back and having a think before jumping in short when, off the top of my head, it's +13% annually since 1950.

Link to comment

Both starting below the pivot (Friday's OHLC) and currently looking to retest, if bears can keep control of the pivot will be looking then for a retest of the recent low but if the bulls can take control will be looking for a retest of the recent highs. Dax with added volume profile just for the look of the thing.

H1 charts;


Link to comment
2 hours ago, tehka said:

I wonder are we going into a repeat of July 2019 where Dow goes range bound between 27000 and 27300?

History repeats itself?

Likely to be caution until the Fed mtg Wednesday, everyone (the big guys) are already all in but have their finger poised over the sell button til confirmed just in case..

Link to comment
20 minutes ago, Kodiak said:

"Our Fed rate monitor calculator is based on CME Group 30-Day Fed Fund futures prices, which tend to signal the markets’ expectations regarding the possibility of changes to US interest rates based on Fed monetary policy. The tool allows users to calculate the likelihood of an upcoming Fed rate hike or cut."



come down because of oil but now Saudi saying oil back on line expectations will reverse back up, 22 hours and counting ta-da.


Link to comment

Dax and Dow starting out just over the pivot so awaiting clearer sign of direction.

Below is a look at yesterday's Dax on a 4 point bar Renko chart; the day started below the pivot (orange) and a failed attempt to break up through on the London open, that was followed by two further rejections before a break down through S1 (red), then a retest and fail leading to a further break down not quite reaching S2. The afternoon saw a complete retrace of the morning's move back up to the pivot.



  • Like 1
Link to comment
5 minutes ago, tehka said:

Have decided to stay away for the next 11 hours or so. Too much risk ahead of interest rate decision unless I want to take a 50-50 chance

Fairly slow going so far and probably likely to remain so, even inspite of the oil move I suspect a rate cut is still fairly well already priced in so may be more of a chance for a move to the downside rather than up, and be wary of the presser, price can swing on every sentence, especially with Powell who has a reputation for putting his foot in it. 

Link to comment

Dax starting just under the pivot and at yesterday's point of control on the volume profile indicator (red bar, highest volume for the day was put through at this level). Dow starts above the pivot after the drive up in the last hour of the US session yesterday. Will be looking for Dow to test the highs and for Dax to follow.

Have added Ftse below which may react to the UK interest rate data today at 12:00, is starting out well below the pivot but just above daily chart support around S1.

H1 charts;



Link to comment

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • General Statistics

    • Total Topics
    • Total Posts
    • Total Members
    • Most Online
      10/06/21 10:53

    Newest Member
    Joined 27/07/21 09:14
  • Posts

    • Gold falls back into support as Brent crude pushes into Fibonacci resistance Gold falls back into key support, while Brent crude has rallied up into Fibonacci resistance in its bid to regain previous highs. Source: Bloomberg    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  Gold drifts back into key support level Gold has been on the back foot once again, with price moving back into the key $1790 support level. A break below that level would bring a bearish picture into play following a period of consolidation. However, with price typically managing to post a short rebound from this level, it is worthwhile expecting another move higher until we see $1790 break. Source: ProRealTime   Brent crude rallies back into Fibonacci resistance Brent crude has been on the rise since a pullback into the wider 76.4% Fibonacci retracement level at $67.60. That rally has brought us back into yet another 76.4% level at $74.12. The wider uptrend points towards a likely push up through this level in a bid to regain the previous peaks of $76.30 and $77.57. However, whether that will come in a straight line remains to be seen. For now, we need to see whether price respects that Fibonacci resistance level or simply pushes through. To the downside, any pullback would need to break the $72.14 level to bring a more bearish short-term outlook. Until then, there is a good chance we see further upside come into play. Source: ProRealTime   See opportunity on a commodity?  
    • Astrazeneca Q2 revenue is expected to show strong growth, although an increased cost base will pressure underlying earnings. Source: Bloomberg   Shares AstraZeneca Price Revenue Earnings before interest, taxes, depreciation and amortization Technical analysis  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When are the AstraZeneca results? AstraZeneca, the biopharmaceutical company, earnings release date is scheduled for 27 July 2021. The scheduled results will cover the groups second quarter (Q2) and half-year earnings. What to expect from AstraZeneca results? While a large Covid-19 vaccine rollout will have boosted revenue for the group, it would have done little for underlying earnings due to the company selling the product as a non-profit item. Consensus estimates derived from Refinitiv data arrives at the following expectations for Q2 of 2021: Revenue $7.530 billion (+20%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.233 billion (-10.75% YoY) Earnings per share (EPS) $0.93 (-3.01% YoY) What is expected to be accretive to future earnings for the group (although may weigh in the short term) is the groups acquisition of biopharmaceutical business Alexion, which was concluded on 21 July 2021, shortly after the reporting quarter. Find out more on how to buy, sell and short AstraZeneca shares How to trade AstraZeneca results A Refinitiv poll of 29 analysts maintain a long-term average rating of ‘buy’ for AstraZeneca (as of 26 July 2021), with 10 of these analysts recommending a strong buy, 16 recommending a buy, 1 hold, 1 sell and 1 strong sell recommendation on the stock. Source: IG AstraZeneca share price – technical analysis view Source: IG charts   The share price of AstraZeneca continues to trade in an uptrend which has been in place since the beginning of 2021. The price has however started to correct from near-term highs. Traders respecting the longer-term uptrend will prefer to keep a long bias to trades targeting a retest of the 8770 level, provided that the price does not move to break the confluence of both trend line and horizontal support at the 7800 level. A break of the 7800 level would instead suggest the uptrend to be broken. In summary AstraZeneca results are scheduled for release on 27 July 2021 Q2 revenue of $7.530 billion is expected Q2 EBITDA of $2.223 billion is expected EPS of $0.93 is expected The average broker rating for AstraZeneca is ‘buy’ The share price of AstraZeneca is currently in a short term correction of a longer-term uptrend
  • Create New...